Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ABVC Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABVC
Nasdaq
8731
https://abvcpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ABVC Biopharma Inc
ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand
- Mar 20th, 2023 11:00 am
ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare
- Mar 14th, 2023 11:00 am
ABVC BioPharma Provides 2023 Pipeline Update
- Feb 28th, 2023 1:30 pm
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
- Feb 23rd, 2023 9:16 pm
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®
- Feb 21st, 2023 1:30 pm
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
- Jan 19th, 2023 1:30 pm
ABVC: Several Potential Paths to Achieving Near-Term Milestones
- Jan 18th, 2023 1:25 pm
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
- Jan 5th, 2023 1:30 pm
ABVC: Key Medical Venues Participating in Clinical Studies
- Dec 20th, 2022 4:05 pm
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
- Nov 17th, 2022 1:30 pm
ABVC BioPharma Third Quarter 2022 Earnings: Beats Expectations
- Nov 17th, 2022 10:16 am
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
- Nov 14th, 2022 11:20 pm
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
- Nov 7th, 2022 1:30 pm
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients
- Nov 2nd, 2022 12:30 pm
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
- Oct 5th, 2022 12:30 pm
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
- Sep 23rd, 2022 12:30 pm
ABVC: Moving Lead Assets Forward and Expanding Development Pipeline
- Sep 16th, 2022 1:36 pm
ABVC Biopharma Announces Letter to Shareholders
- Sep 13th, 2022 12:30 pm
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
- Sep 9th, 2022 12:30 pm
ABVC Provides Oncology Pipeline Updates
- Aug 22nd, 2022 12:30 pm
Scroll